SCHEMBL24422909

SCHEMBL24422909

COC(=O)c1ccc2[nH]nc(F)c2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 2/20 0.54
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 2/20 0.50
HPGD P15428 1/20 0.50
HSD17B10 Q99714 1/20 0.50
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
STAT3 P40763 1/20 0.48
HIF1A Q16665 1/20 0.48
FLT3 P36888 1/20 0.47
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
KIF11 P52732 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
PARP1 P09874 2/20 0.46
ATM Q13315 1/20 0.46
GPR84 Q9NQS5 1/20 0.45
CREBBP Q92793 1/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1501529 0.83 KDM4E (0.55) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2671105 0.83 MAP2K4 (0.52) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL16929779 0.83 JAK2 (0.58) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL29564826 0.82 MAP2K4 (0.54) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2569247 0.82 KDM4E (0.50) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL29301471 0.82 KDM4E (0.50) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL23675227 0.82 MAP2K4 (0.54) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL9985941 0.82 KDM4E (0.54) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL30159599 0.82 KDM4E (0.50) MAP2K4KDM4EALDH1A1HPGDHSD17B10
SCHEMBL30147682 0.81 MAP2K4 (0.48) MAP2K4KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12606541-B2 PPARg modulators and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2026-04-21 US disclosed
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS BRIDGE MEDICINES 2025-05-01 US disclosed
CN-117858877-A C-linked inhibitors of ENL/AF9 YEATS 桥梁药品有限公司 2024-04-09 CN disclosed
CN-116635380-A PPARgamma modulators and methods of use 卫材R&D管理有限公司 2023-08-22 CN disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-03-02 US disclosed
WO-2022099144-A1 ΡΡΑRγ MODULATORS AND METHODS OF USE Eisai R&D Mangement Co., Ltd. (JP) 2022-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230062861-A1 PPARg MODULATORS AND METHODS OF USE PPARG, PPARA, PPARD MAP2K4 3598/4885KDM4E 3945/4885ALDH1A1 542/4885
US-12606541-B2 PPARg modulators and methods of use PPARG, PPARA, PPARD MAP2K4 2609/4885KDM4E 2304/4885ALDH1A1 1374/4885
US-20250136592-A1 C-LINKED INHIBITORS OF ENL/AF9 YEATS MLLT3, MLLT1, YEATS2 MAP2K4 4241/4885KDM4E 186/4885ALDH1A1 1756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.